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Upregulation of the RAS-RAF-MEK-ERK-MAPK pathway is involved in the development
of several human tumors, aortic aneurysms, atherosclerosis, and cardiomyopathy.
Refametinib, a highly selective MEK-inhibitor, has already shown antineoplastic activity
in phase II trials. Furthermore, it showed potency to attenuate aortic root growth in murine
models. Current formulations of this drug however necessitate oral gavage as a delivery
method for long-term studies, which is labor-intensive and induces stress and occasional
injury, potentially confounding results. Therefore, we developed a novel oral administration
method for refametinib. A 2-hydroxypropyl-beta-cyclodextrin (HPBCD) based drinking
water preparation of refametinib was formulated, for which a selective, analytical UHPLC-
UV method was developed to assess the in-use stability. Next, 16 week old male wild-
type C57Bl/6J mice received either a daily dose of 50 or 75 mg/kg/day refametinib or were
given regular drinking water during 7 days. In both dosage groups the refametinib plasma
levels were measured (n = 10 or 7, respectively). Furthermore, pERK/total ERK protein
levels were calculated in the myocardial and aortic tissue of mice receiving a daily dose
of 50 mg/kg/day refametinib and untreated mice (n = 4/group). After 7 days no
significant degradation of refametinib was observed when dissolved in drinking water
provided that drinking bottles were protected from UV/visible light. Furthermore, a dose-
dependent increase in refametinib plasma levels was found whereby active plasma levels
(> 1.2 µg/mL) were obtained even in the lowest dose-group of 50 mg/kg/day. A significant
reduction of pERK/total ERK protein levels compared to untreated mice was observed in
aortic and myocardial tissue of mice receiving a daily dose of 50 mg/kg/day refametinib.
Importantly, a relatively high mortality rate was noted in the highest dose group (n = 5).
This approach provides a valid alternative oral administration method for refametinib with a
reduced risk of complications due to animal manipulation and without loss of functionality,
which can be implemented in future research regarding the malignant upregulation of thein.org August 2020 | Volume 11 | Article 13361
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toxic dose.Keywords: refametinib (RDEA119, BAY 86-9766), RAS-RAF-MEK-ERK-MAPK pathway, murinemyocardium, murine
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The MAPK (mitogen-activated protein kinase) pathway is
involved in the regulation of a plethora of processes including
apoptosis, cell cycle progression, metabolism, cell migration,
differentiation and proliferation (Wortzel and Seger, 2011).
The pathway consists of different signaling arms, including
extracellular signal-regulated kinase (ERK-1 and -2), Jun N-
terminal kinase (JNK) and p38 (Derynck and Zhang, 2003).
Upstream activators of ERK-1 and -2 are MEK-1 and -2, which
are in turn activated by RAS/RAF signaling. And finally, the
entire RAS-RAF-MEK-ERK-MAPK signal cascade can be
activated through phosphorylation via the activation of signaling
cascades by an abundance of growth factors and cytokines,
including transforming growth factor-b (TGFb) (Derynck and
Zhang, 2003).
Increased or constitutive activation of the RAS-RAF-MEK-
ERK-MAPK pathway, either through gain-of-function pathogenic
variants in oncogenes or hyperactivation of upstream pathways,
has been observed in several human tumors, including lung,
colon, melanoma, thyroid, and pancreatic cancer (Grandis and
Sok, 2004; Hynes and Lane, 2005; Schubbert et al., 2007; Wang
et al., 2007; Murugan et al., 2009). In addition, ERK-1 and -2
activation has also been shown to contribute to aortic aneurysm
progression (Holm et al., 2011; Yang et al., 2016), atherosclerosis
(Chen et al., 2015; Zhang et al., 2016; Li X. J. et al., 2016) and
dilated and hypertrophic cardiomyopathy (Wu X. et al., 2011;
Cook et al., 2014; Campens et al., 2015; Li C. et al., 2016; Rouf
et al., 2017). It has been reported that inhibition of ERK-1 and -2
phosphorylation increases the elastin synthesis both in vitro (in
vascular smooth muscle cells) and in vivo (in rat aorta) thereby
highlighting ERK-1 and -2 inhibition as a potential treatment for
vascular pathologies characterized by reduced arterial elastin
content (Lannoy et al., 2014). Furthermore, MEK-inhibition
also has antiatherogenic properties as MEK-inhibition
combined with activation of liver X receptor (LXR)
significantly inhibited the development of atherosclerosis in
ApoE deficient (ApoE-/-) mice through reverse cholesterol
transport and by blocking the formation of foam cells (Chen
et al., 2015; Li X. J. et al., 2016; Zhang et al., 2016). In a transgenic
rabbit model for human hypertrophic cardiomyopathy (b-MHC-
Q403) MEK-inhibition mitigated the cardiac hypertrophic
phenotype and improved the cardiac function (Patel et al.,
2001). Furthermore, treatment of LmnaH222P/H222P mice,
known to develop dilated cardiomyopathy, with ERK
inhibitors prevented left ventricular dilatation, decreased
myocardial fibrosis and blocked increased RNA expression
of natriuretic peptide precursors (Wu W. et al., 2011). In
addition, MEK-inhibition prevented enlargement of the cardiacin.org 2myocytes and fetal gene reactivation in an in vitro model for
cardiac hypertrophy (Li C. et al., 2016). Altogether, these
preclinical studies encourage the use of MEK-inhibitors as a
strategy to target vascular pathologies and cardiomyopathy
caused by an aberrant activation of the RAS-RAF-MEK-ERK-
MAPK pathway.
Refametinib (also known as RDEA119 or BAY 86-9766) is a
known highly selective, potent and allosteric inhibitor of MEK-1
and -2 (Iverson et al., 2009). Compared to first generation MEK
inhibitors, refametinib has been shown to have reduced activity
in the brain and a modest cardiovascular toxicity with solely
sporadic prolongations of the QT-intervals and reduced
ventricular ejection fractions in a small subgroup of cancer
patients (Allen et al., 2003; Rinehart et al., 2004; LoRusso et al.,
2005; Brown et al., 2007; Weekes et al., 2013). Refametinib is
therefore an attractive treatment option for the abovementioned
ERK-associated malignant manifestations. Currently, several
reports have shown that the compound (either alone or in
combination with other therapeutic compounds) has both
in vitro and in vivo antitumor activity in multiple preclinical
cancer models by inducing cell cycle arrest or apoptosis (Chang
et al., 2010; Schmieder et al., 2013; Dilly et al., 2015; Troiani
et al., 2015). Clinical trials for various solid tumors have already
proven the positive effect of MEK inhibition on tumor growth
(Weekes et al., 2013; Lim et al., 2014; Kiessling and Rogler, 2015;
Van Laethem et al., 2017). Refametinib has also been used
successfully in a mouse model for Marfan syndrome (MFS,
Fbn1C1039G/+), a syndrome associated with aortic aneurysm,
attenuating aortic root growth after two months of treatment
compared to placebo-treated mice (Holm et al., 2011). In
addition, refametinib treatment also ameliorated aortic disease
(decreasing aortic diameters and preventing intimal-medial
tears at an early stage of disease) in smooth muscle cell
(SMC)-specific Tgfbr1 deleted (Tgfbr1iko) mice (Yang et al.,
2016). Finally, exacerbated aortic aneurysms and premature
death observed in MFS mice treated with Ca2+-channel
blockers could also be rescued upon refametinib treatment
(Doyle et al., 2015).
The current standard dosing strategy for refametinib in
preclinical animal trials consists of a twice-daily oral gavage for
the duration of the treatment period. However, oral gavage
induces significant stress and occasional injury in rodents
which can contribute to confounding results by dosing-
induced stress even when an appropriate sham group is
included in the study (Brown et al., 2000; Balcombe et al.,
2004; Bonnichsen et al., 2005; Vandenberg et al., 2014). Based
on the 3 Rs principle (i.e. reduction, replacement and
refinement), alternative methods for oral gavage have been
investigated to alleviate the suffering and distress experiencedAugust 2020 | Volume 11 | Article 1336
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2014), such as administration via drinking water or food.
To the best of our knowledge, no alternative stress-free routes for
administration (e.g. via drinking water) are currently explored or
available for administering refametinib to laboratory animals.
Refametinib is water insoluble and typically administered via oral
gavage using 2-hydroxypropyl-beta-cyclodextrin (HPBCD) (Holm
et al., 2011) and cremophor EL, a surfactant in saline (Chang et al.,
2010), as vehicle. As such, we focused our efforts on the evaluation
of a suitable drinking water formulation by the development of an
analytical method to evaluate the stability for this novel formulation
in a preclinical setting. Furthermore, we evaluated the
pharmacodynamics/-kinetics of refametinib supplemented
drinking water in wild-type C57Bl/6J mice. We assessed the
refametinib plasma concentrations as well as the ERK inhibitory
potential of refametinib in murine myocardial and aortic tissue after
7 days of treatment.MATERIALS AND METHODS
Chemicals and Reagents
Refametinib (chemical formula: (S)-N-(3,4-difluoro-2-(2-
fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-
dihydroxypropyl) cyclopropane-1-sulfonamide, > 99% chemical
and optical purity) was purchased from ChemieTek
(Indianapolis, IN, USA). Acetonitrile and methanol of ultra-
high performance liquid chromatography (UHPL)-gradient
grade were obtained from Fisher Scientific (Merelbeke,
Belgium). Water for UHPLC was purified by an Arium 611
purification system (Sartorius, Göttingen, Germany), yielding ≥
18.2 MΩ x cm quality water. Formic acid (UHPLC/MS grade)
was purchased from Fisher Scientific (Merelbeke, Belgium),
hydrogen peroxide 30% w/w was from Merck (Overijse,
Belgium) and 2-hydroxypropyl-b-cyclodextrin (HPBCD,
kleptose, oral grade, concentration/purity ≥ 97%) was from
Roquette (Lestrem, France). All other chemicals were from Sigma
Aldrich (Overijse, Belgium) and HPLC vials were from Waters
(Zellik, Belgium).
Preparation of Refametinib Drinking
Water Formulation
Refametinib was complexed with HPBCD as previously
described (Bouquet et al., 2007) with minor adaptations. The
desired amount of refametinib was dissolved in absolute ethanol
in a ratio of 1/60 w/w. HPBCD was added to the solution to
obtain a refametinib/HPBCD ratio of 1/60 mol/mol and the
solution was placed in an ultrasonic bath for 5 min. More
absolute ethanol was added to obtain a final refametinib/
ethanol ratio of 1/223 w/w. Next, phosphate-buffered saline
(PBS) was added in a ratio of 2/1 w/w (PBS/HPBCD). Then,
the solution was aliquoted in vials and freeze dried (program
described in Supplemental Table S1) in a Christ gamma 1-16
LSC freeze dryer (Analis s.a.-n.v., Suarlee, Belgium) to obtain a
white amorphous powder. After lyophilisation, the refametinib
containing vials were stored at −35°C and protected from light.Frontiers in Pharmacology | www.frontiersin.org 3UHPLC Method
In order to evaluate the inclusion procedure and to measure the
amount of refametinib that was complexed with HPBCD, an
amount of freeze dried material was dissolved in tap water to a
final concentration of 0.1 mg refametinib/mL, followed by
centrifugation (20,000 g for 30 min) and filtration (Whatman®
qualitative filter paper Grade 1). In addition, a refametinib
standard was prepared in 10% methanol in water (regarded as
the 100% concentration-value). The concentration of dissolved
refametinib in all samples was determined using an adjusted
UHPLC-UV method.
Chromatography was performed using a Water Alliance
UHPLC (Waters Corporation, Zellik, Belgium; 375 μL dwell
volume) consisting of an autosampler, quaternary pump and
Waters Empower chromatographic software. The sample
compartment was kept at 5°C (± 2°C), the column was a
100 mm x 2.1 mm, 1.7 μm Acquity UHPLC BEH C18 column
(Waters Corporation, Zellik, Belgium) held at 40°C (± 5°C),
applying a constant flow rate of 0.5 mL/min and using an
injection volume of 2.0 μL. Mobile phases were 80/20 (V/V)
H2O/acetonitrile (ACN) supplemented with 0.1% formic acid
(FA) (W/V) (mobile phase A) and 90%/10% ACN/H2O
supplemented with 0.1% FA (W/V) (mobile phase B). The
gradient elution was as follows: mobile phase B was held at 0%
during the first 1 min, then increased to 100% in 11 min and held
at 100% for 1 min. Then mobile phase B was brought back to 0%
in 1 min and held to the original condition for 4 min to enable
equilibration of the start conditions, yielding a total run time
of 18 min.
Detection was performed using a Waters Photo Diode Array
(PDA) Detector (Waters Corporation, Zellik, Belgium) between
190 and 400 nm, with quantification at 230 nm. A reporting
threshold of 0.05% of the main peak (i.e. the compound of
interest) was applied.
Mass spectrometry for identification of degradants was
performed on a Waters Acquity UPLC-MS/MS system, the
Synapt G2-Si, (Waters Corporation, Zellik, Belgium) operating
in positive ion mode. The nebulization gas was set to 7.00 bar, the
desolvation gas flow at 1000 L/h at a temperature of 500°C, the
cone gas set to 150 L/h, and the source temperature set to 150°C.
A capillary voltage and a cone voltage were set to 3.00 kV and
20 V, respectively. The MS scan mode was set to 50-800 m/z.
Argon was employed as the collision gas at 0.16 mL/min. The
molecular formula was predicted using a recursive algorithm as
previously described (Patiny and Borel, 2013).
Refametinib Stability Study
In order to analyze the stability of refametinib dissolved in
drinking water under different commonly observed conditions
in animal facilities, the lyophilised refametinib/HPBCD complex
was dissolved in tap water to obtain a final concentration of 0.26
mg refametinib/mL and sonicated for 40 min followed by
filtration as previously described. Next, the refametinib
solution was divided over the different recipients as follows:
For the adsorption study, three 250 mL drinking bottles were
filled with 40 mL of refametinib solution and stored horizontal,August 2020 | Volume 11 | Article 1336
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refametinib solution and stoppered and additionally, three 10 mL
volumetric flasks were filled with placebo (i.e. 38 mg/mLHPBCD in
tap water) and stoppered. Both the drinking bottles as the
volumetric flasks were protected from UV/VIS light by means of
aluminum foil wrapping. Subsequently, the drinking bottles and
volumetric glass flasks were either stored at 5°C, 25°C/60% relative
humidity (RH) or 40°C/75% RH.
For the light stability study, three drinking bottles, of which
one was wrapped in aluminum foil (= control, protected from
light), were filled with 40 mL of refametinib solution and placed
horizontal for storage in a UV and visible light chamber at 25 ±
2°C and 60 ± 5% RH.
For the in-use study, 40 mL of refametinib solution was
delivered to the mouse facility at the Ghent University
Hospital (average minimum-maximum temperature and
relative humidity: 19–24°C and 41–59% RH) and placed in a
drinking bottle wrapped in aluminum foil.
Next, for all abovementioned studies, samples were taken
immediately (t0) and at 7 days (t7) for further UHPLC analysis.
The percentage refametinib recovery at t7 was calculated, relative
to the percentage refametinib recovery at t0 and chromatograms
were analysed for potential degradation peaks.
Mice
The 16 weeks old male wild-type C57Bl/6J mice were kept in
accordance with the institutional guidelines regarding the care,
housing and use of laboratory animals, which are based on the
European Parliament Directive 2010/63/EU. The procedure was
approved by the Ethics Committee for the care and use of
laboratory animals of the Ghent University Hospital (EC 15/77).
Pharmacological Treatment and Sample
Collection Mice
Based on previously recorded average daily drinking volume in
wild-type C57Bl/6J mice (see Supplemental Table S2) a
sufficient amount of lyophilized refametinib/HPBCD complex
was dissolved in drinking water as previously described in
Section 2.2 in order to obtain refametinib concentrations of 50
or 75 mg/kg/day. These concentrations were based on the study
of Iverson et al. (2009) as they reported that an active refametinib
plasma concentration of at least 1.2 μg/mL was reached after
twice-daily administration of 25 mg/kg. The additional higher
dosage of 75 mg/kg/day refametinib was also included in order to
buffer potential variations in water uptake, even though drinking
behavior was not influenced by addition of refametinib when
evaluated prior to initiation of treatment.
Drinking bottles were protected from light with aluminum
foil and the volume was carefully documented. Next, a total of 16
mice received 50 mg/kg/day refametinib (group 1), 12 mice
received 75 mg/kg/day refametinib (group 2), and 4 mice were
given regular drinking water (group 3). After 7 days of treatment
approximately 200 mL blood was collected from the tail vein in
EDTA tubes (BD Microtainer K2E, BD Biosciences), for plasma
bioanalyses (subgroup of group 1, n = 10, and all surviving mice
of group 2, n = 7). Blood collection was performed at differentFrontiers in Pharmacology | www.frontiersin.org 4time points (morning, noon and evening) and executed once in
each individual mouse in order to evaluate the stability of the
refametinib plasma concentration throughout the entire day.
This procedure was performed under general anesthesia (1–1.5%
isoflurane mixed with 0.5 L/min 100% O2). Subsequently, the
blood samples were centrifuged for 10 min at 1,000–2,000 g and
4°C. Plasma was aliquoted into new tubes and stored at −80°C
prior to analysis.
Plasma Bioanalysis
Plasma samples were analyzed for refametinib using a UHPLC-
tandem mass spectrometry (UHPLC-MS/MS) method. Prior to
analysis, samples were diluted 1/25 in water and vortexed for 5 s.
Subsequently, 50 μL was taken for the sample preparation
procedure adapted from Iverson et al. (2009). In short, 200 μL
of the internal standard (20 ng/mL) dissolved in 1% formic acid/
5/95 V/V acetonitrile/H2O was added to the sample and vortexed
for 15 s. Next, samples were centrifuged for 15 min at 20,000 g at
room temperature. Finally, the supernatant was collected and
analyzed by means of UHPLC-MS/MS in order to obtain the
refametinib plasma concentration.
Protein Expression Studies
Mice receiving 50 mg/kg/day refametinib (no blood draw
performed) and untreated mice were sacrificed (n = 4/group)
by means of CO2 overdose (1.0 L/min). Hearts and aortae were
flushed in situ with 1x phosphate buffered saline (PBS) and
dissected. Tissue samples were kept on ice and homogenized by
mixing or crushing in lysis buffer (RIPA, Sigma-Aldrich)
complemented with protease inhibitors (Complete protease
inhibitor cocktail tablets, Roche) and phosphatase inhibitors
(Cocktail II and III, Sigma-Aldrich) at a 30% (W/V) ratio.
Lysates were centrifuged at 20,000 g at 4°C for 30 min and
supernatants were collected and stored at −80°C until further
processing. Total protein concentration of the samples was
determined using the Pierce BCA (bicinchoninic acid) 660 nm
Protein assay kit (Thermo Fisher Scientific). Protein samples
(50 μg) diluted to a total volume of 20 μL with PBS were reduced
by adding 2 μL 1 M dithriothreitol (Sigma-Aldrich) and
incubation at 95°C for 5 min. Next, samples were loaded on a
NuPage 4–12% Bis-Tris gel (Invitrogen) together with 5x non-
reducing lane marker sample buffer (Thermo Fisher Scientific).
Following SDS-PAGE electrophoresis, proteins were transferred
onto a nitrocellulose membrane (Invitrogen) by means of the
iBlot 2 dry blotting system (Thermo Fisher Scientific). The
membrane was blocked in 2% bovine serum albumin for one
hour and incubated overnight at 4°C with the primary antibody
rabbit monoclonal anti-phospho-p44/42 MAPK (pERK) (1:2000,
Cell Signalling Technologies). Next, membranes were incubated
with a secondary antibody, anti-rabbit IgG HRP-linked (1:5000,
Cell Signaling Technologies) for 1 hour at 4°C. Subsequently,
membranes were incubated with the SuperSignal West Dura
luminol-based ECL HRP substrate (Thermo Fisher Scientific) for
5 min at room temperature. Membranes were scanned using the
Chemidoc-it imaging system (UVP, Sopachem). After imaging,
the blots membranes were incubated in stripping buffer (ThermoAugust 2020 | Volume 11 | Article 1336
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chemiluminescence)-Advance blocking buffer (GE Healthcare)
for 2 h. Subsequently, the entire process was repeated with the
primary antibody rabbit polyclonal anti-p44/42 MAPK (ERK)
(1:1000, Cell Signaling Technologies). Quantification of the
immunoblots was performed using Image J software (v. 1.44p).
Statistics GraphPad Prism version 8.0.0 (GraphPad Software, San
Diego, California USA) was used for statistical analyses and
generating graphs. Independent two-sample t-test was
performed on the obtained values of the refametinib stability
study, refametinib plasma levels and protein expression studies.
Results are shown as mean ± standard error. A p-value of < 0.05
was used to define statistical significance (two-sided).RESULTS
Refametinib Stability Study
Reconstitution of the lyophilized refametinib/HPBCD complex
in tap water, at a ratio of 1/60 mol/mol, resulted in an inclusion
efficiency of 100%. Hence, the solubilisation protocol described
in Section 2.2 was used for all following experiments. The results
of the stability study are summarized in Table 1. Based on the
95% confidence interval on the assay values (i.e. the recoveries)
of the controls, degradation of refametinib was considered
significant when the recovery would be below 90%. A second
criterion, which is more sensitive and discriminatory, is the
appearance of degradation peaks in the chromatograms
(Figure 1). Refametinib was stable in the volumetric glass
flasks at all examined conditions, i.e. no degradation peaks
were observed and an assay recovery (t0/t7) of > 96% was
obtained (Figures 1A–C). As for the drinking bottles stored
under the same conditions, no significant loss due to adsorption
was observed (independent two-sample t-test, p > 0.05) which
was confirmed by the absence of degradation peaks on the
chromatograms (Figures 1D–F). The assay values of the UV
light treated refametinib solution at t7 amounted to 97%.
However, a degradation peak with a retention time (RT) of
6.1 min was observed at t7 (0.7% of the refametinib peak area at
t0), whereas the control sample did not reveal any degradation
based on the absence of degradation peaks in the chromatogramFrontiers in Pharmacology | www.frontiersin.org 5(Figures 1G, H). The assay value of the VIS light treated
refametinib compound at t7 amounted to 95% and similarly to
the UV light treatment, a degradation peak with a RT of 6.1 min
was observed at t7 (1.4% of the refametinib peak area at t0)
(Figure 1I). The main degradant (relative retention time (RRT)
to refametinib = 0.8) was identified as C19H21F3N2O5S which was
confirmed by the experimentally obtained isotopic distribution
versus the theoretical distribution, with a high correlation
between the relative intensities of the corresponding peaks in
both spectra (R² = 0.9996) and the MS/MS-spectra (Figure 2).
Furthermore, for the in-use conditions, the refametinib assay
recovery value was 91% (Table 1), i.e. above 90%, and no
degradation peak was observed (Figure 1J); hence, a sufficient
stability under these in use conditions was concluded.
Dose-Dependent Increase in Refametinib
Plasma Levels
After 7 days of refametinib treatment significant plasma levels of
refametinib could be observed in both dosage groups, 50 or 75
mg/kg/day refametinib. Furthermore, with increasing dose of
refametinib in the drinking water, the plasma levels of
refametinib increased (3.62 ± 1.79 mg/mL for 50 mg/kg/day;
7.67 ± 5.14 mg/mL for 75 mg/kg/day), though this increase was
not statistically significant (independent two-sample t-test, p =
0.085) (Figure 3). In addition, no significant difference in
refametinib serum concentration could be observed between
the different time points of blood collection within each dosage
group (data not shown). With the exception of one mouse, all
observed refametinib plasma levels were above 1.2 μg/mL (red
line in Figure 3), which was previously reported to be an active
refametinib plasma concentration (Iverson et al., 2009). During
refametinib treatment, one out of sixteen mice receiving 50 mg/
kg/day refametinib and five out of twelve mice receiving 75 mg/
kg/day refametinib died (Figure 4).
Refametinib Is a Potent Inhibitor of
ERK Activation
We compared the level of phosphorylated ERK (pERK) in
myocardial and aortic tissue of treated (50 mg/kg/day
refametinib) and untreated mice (n = 4/group). Mice receiving
75 mg/kg/day refametinib were not included in this study due to
the high death rate previously observed in this dosage group.
Administration of refametinib supplemented drinking water
strongly suppressed pERK levels in the myocardial and aortic
tissue of mice treated for 7 days with refametinib supplemented
drinking water compared to untreated mice (a reduction of
approximately 42 and 82% respectively, independent two-
sample t-test, p ≤ 0.0169) (Figure 5).DISCUSSION
In the current study we propose an alternative to oral gavage of
refametinib, a MEK-1 and -2 inhibitor, which requires less
hands-on time, and evokes no stress in laboratory animals. We
dissolved refametinib in the drinking water of mice without lossTABLE 1 | Summary of the refametinib assay values in volumetric flasks and
drinking bottles at t7 relative to t0 (n = 1).
Container Conditions Percentage refametinib
recovery at t7
Volumetric flask 5°C 99%
25°C/60% RH 99%
40°C/75% RH 96%
Drinking bottle 5°C 93%
25°C/60% RH 93%
40°C/75% RH 99%
Light control, 25°C/60% RH 96%
UV treated, 25°C/60% RH 97%
VIS treated, 25°C/60% RH 95%
In use conditions 91%RH, relative humidity; UV, ultraviolet light; VIS, visible light.August 2020 | Volume 11 | Article 1336
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levels in the murine myocardial and aortic tissue after 7 days
of treatment.
We report that HPBCD has a high affinity for refametinib,
thereby inducing a significant increase of refametinib solubility,
which allowed the drug to be dissolved in laboratory animalFrontiers in Pharmacology | www.frontiersin.org 6drinking water. Furthermore, a selective gradient UHPLC
method was developed to evaluate the stability of refametinib
supplemented water during different environmental conditions.
Overall, the developed UHPLC method met the selectivity and
precision requirements for our purposes as degradation products
of refametinib could be clearly separated from refametinib itself.A B
D
E F
G
I
H
J
C
FIGURE 1 | UHPLC chromatograms of dissolved refametinib/HPBCD complex stored for 7 consecutive days under different conditions. (A–C) represents the
obtained chromatograms of dissolved refametinib/HPBCD complex stored for 7 days in a volumetric flask at 5°C, 25°C/60% RH and 40°C, 75% RH, respectively.
No degradation peaks could be observed at any of these conditions. (D–F) represents the obtained chromatograms of dissolved refametinib/HPBCD complex
stored for 7 days in drinking bottles at 5°C, 25°C/60% RH and 40°C, 75% RH, respectively. The use of drinking bottles did not result in any adsorption of
refametinib as no degradation peak could be observed. (G–I) representative chromatograms of the content of a control versus treated drinking bottle filled with
dissolved refametinib/HPBCD complex and stored in a UV cabinet and VIS cabinet at 25°C/60% RH for 7 consecutive days, respectively. UV-treatment resulted in
the appearance of a degradation peak with a retention time of 6.1 min in the chromatogram (indicated with arrow). VIS-treatment resulted in a degradation peak at
6.1 min (indicated with arrow). (J) representative chromatogram of dissolved refametinib/HPBCD complex in a drinking bottle stored for 7 days under “in use
conditions”. No degradation of refametinib could be observed based on the absence of degradation peaks. AU, absorbance units; RH, relative humidity; UV,
ultraviolet light; VIS, visible light.August 2020 | Volume 11 | Article 1336
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observed in the drinking bottles stored at different temperatures
and RH and during in-use conditions. In contrast, degradation of
refametinib was observed in drinking bottles stored for 7 days in
UV- and VIS-cabinets, with a higher percentage of degradation
products observed in the latter based on the chromatograms. The
drinking bottles were made of clear polycarbonate (PC). In
general, PC is almost completely transparent throughout the
entire visible region until 400 nm, blocking the majority of UV
light explaining why degradation is higher in the drinking bottlesFrontiers in Pharmacology | www.frontiersin.org 7exposed to VIS. As refametinib contains a sulfonamide moiety it is
likely prone to photocatalytic degradation in aqueous solutions
(Baran et al., 2006; Garcia-Galan et al., 2008). Photocatalytic
cleavage of refametinib might result in the formation of an
aromatic amine, which is potentially carcinogenic (Benigni
and Bossa, 2006). However, as the main degradation product
of refametinib after UV/VIS exposure was identified as
C19H21F3N2O5S there is no evidence for photocatalytic cleavage
of the sulfonamide site. Therefore, formation of the carcinogenic
aromatic amine is not likely. In conclusion, we have successfullyAugust 2020 | Volume 11 | Article 1336A
B
FIGURE 2 | Identification of the main degradant from the VIS light treated samples at t7. (A) MS-spectra of the refametinib degradant (RRT to refametinib = 0.8).
* The peaks with an m/z of 268.0938 and 233.0625 are assigned as potential daughter molecules from the degradant after insource fragmentation. (B) The
proposed chemical degradation of refametinib to C19H21F3N2O5S after UV-treatment.
Steijns et al. Solubilized Refametinib Inhibits MEK1/2dissolved refametinib in drinking water without any significant
adsorption nor degradation provided that drinking bottles are
wrapped with aluminum foil to exclude formation of degradation
compounds. Furthermore, the described formulation might
also offer a novel strategy for administration of other water
insoluble compounds.
Next, we demonstrated that refametinib supplemented water
uptake for 7 days resulted in a sufficiently high active refametinib
plasma concentration in all but one wild-type mice for both
doses [> 1.2 mg/mL (Iverson et al., 2009)]. The insufficientFrontiers in Pharmacology | www.frontiersin.org 8refametinib plasma concentration (1.010 μg/ml refametinib)
observed in the abovementioned single mouse might be due to
a relatively low daily water uptake (2.5 mL, lowest observed water
uptake) as a result of stress as cage mates belonged to the
morning blood draw group whereas the blood draw of the
respective mouse took place in the evening.
Significant mortality was observed in the group receiving
the highest dose of 75 mg/kg/day refametinib (5 out of
12, 42%). Although increased or constitutive activation of the
RAS-RAF-MEK-ERK-MAPK pathway is involved in several
pathophysiological manifestations, this pathway is well known to
exert a cytoprotective function during physiological conditions
(Widmann et al., 1999; Gallo et al., 2019). In addition,
downregulation of the RAS-RAF-MEK-ERK-MAPK pathway has
been associated with cardiotoxicity as ERK activation plays an
important role in preventing the transition from adaptive
hypertrophy to heart failure during pressure overload (Harris
et al., 2004; Mutlak et al., 2018; Gallo et al., 2019). The otiose
inhibition of the RAS-RAF-MEK-ERK-MAPK pathway as a result
of high refametinib plasma concentrations might thus be related to
the high death rate in the 75 mg/kg/day dosage group. Furthermore,
the high variability in refametinib plasma concentration observed
in the remaining surviving mice allocated to the high dosage group
might also be related to the negative side effects of excessive RAS-
RAF-MEK-ERK-MAPK pathway inhibition resulting in morbidity
in these mice with subsequent reduced refametinib supplemented
water uptake. Regarding the sole case of mortality observed in the
lower dosage group of 50 mg/kg/day it is plausible that this mouse
was not in an optimal condition prior to the start of the refametinib
treatment considering the time of death at the beginning of
the treatment.
Finally, administration of 50 mg/kg/day refametinib
supplemented water during 7 days effectively reduced ERK-1
and -2 activation in both myocardial and aortic tissue of wild-
type C57Bl/6J mice compared to untreated mice (reduction up to
42 and 82%, respectively). Thus, no loss of function of refametinib
was observed as a consequence of the protocol used to dissolve
refametinib in the drinking water.
In conclusion, we developed a method to dissolve refametinib in
the drinking water of laboratory animals. We showed that mice are
willing to drink refametinib supplemented water resulting in active
refametinib plasma concentrations which effectively reduced ERK-1
and -2 activation in murine myocardial and aortic tissue.
Refametinib dissolved in drinking water offers a novel strategy for
MEK-1 and -2 inhibition in future preclinical research. However,
high dosages of dissolved refametinib should be avoided as these are
associated with toxic side effects.LIMITATIONS
Since this study was not designed to investigate the toxic effects
of refametinib, we did not follow up on the mortality that was
observed in the higher dosage group of 75 mg refametinib/kg/
day. As observed both in our study and the study of Iverson et al.
(2009) the refametinib plasma concentration strongly correlatesAugust 2020 | Volume 11 | Article 1336FIGURE 3 | Refametinib plasma levels. Presence of refametinib was
observed in the plasma of mice after administration of 50 or 75 mg/kg/day
refametinib supplemented drinking water for 7 days. No significant difference
in refametinib plasma levels was observed between the different dosage
groups (independent two-sample t-test, p = 0.085). Red line at 1.2 µg/mL
represents active refametinib serum concentrations previously observed by
Iverson et al. (2009).FIGURE 4 | Survival rate within each refametinib dosage group. One mouse
out of 16 died during treatment with 50 mg/kg/day refametinib. Five out of 12
mice died during treatment with 75 mg/kg/day refametinib.
Steijns et al. Solubilized Refametinib Inhibits MEK1/2with the administered dose. The higher toxicity observed could
thus be due to the administered dose exceeding the toxic level,
which should be explored further in follow-up studies.DATA AVAILABILITY STATEMENT
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(A) and aortic (B) tissue of mice treated for 7 days with 50 mg/kg/day refametinib supplemented drinking water compared to untreated mice. pERK expression was
calculated based on the total ERK expression after which values were normalized to the mean value of untreated mice. Western blots of pERK and total ERK levels
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